價格 | ¥198 | ¥359 | ¥732 |
包裝 | 5mg | 10mg | 25mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-09-29 |
中文名稱:地卓亞平馬來酸鹽 | 英文名稱:Dizocilpine Maleate |
CAS:77086-22-7 | 品牌: TargetMol |
產地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 99.96% | 產品類別: 抑制劑 |
貨號: T3320 |
名稱 | Dizocilpine Maleate |
描述 | Dizocilpine Maleate (MK 801) is a potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) with Kd of 37.2 nM in rat brain membranes. The drug has been considered for the wide variety of neurodegenerative conditions or disorders in which NMDA receptors may play an important role. |
激酶實驗 | Cerebral cortices from male Sprague-Dawley rats (200-300 g) are homogenized in 9 volumes of ice-cold 0.32mol/Lsucrose by nine strokes with a Teflon/glass homogenizer at 500 rpm. The homogenate is centrifuged for 10 min at 1×103 g, and the supernatant is recentrifuged at 1×104 g for 20 min at 4°C. The pellet is suspended in assay buffer (118 mM NaCl/4.7 mM KCl/1.2 mM MgSO4/5 mM NaHCO3/20 mM Hepes/1.2 mM KH2PO4/2.5 mM CaCl2/11 mM glucose, pH 7.4) and incubated at 23°C for 20 min prior to final centrifugation at 1×103 g for 20 min at 4°C. The pellet is resuspended in assay buffer (70 mL per gram of original tissue). Binding of [3H]MK-801 is measured by incubating 750 μL duplicate aliquots of this crude membrane suspension (=0.75 mg of protein) with 100 μL of buffer containing displacer or of buffer alone (total binding), 100 μL of 50 nM [3H]MK-801, and 50 μL of buffer for 60 min at 23°C. Nonspecific binding is defined by 100 μM (final concentration) unlabeled MK-801. |
體外活性 | [3H]MK-801 labels high-affinity binding sites in rat cerebral cortical membranes in a saturable manner. MK-801 produces a potent blockade of depolarizing responses to NMDA in rat cerebral cortical slices. The only compounds that are able to compete for [3H]MK-801 binding sites are substances known to block the responses of excitatory amino acids mediated by the NMDA receptor subtype. [1] MK-801 inhibits N-methyl-D-aspartate-induced [3H]norepinephrine (NE) release and [3H]TCP binding in the hippocampus with IC50 of 20 nM and 9 nM, respectively. [2] MK-801 causes a progressive, long-lasting blockade of current induced by NMDA. Mg2+ (10 mM) prevents MK-801 from blocking the N-Me-D-Asp-induced current, even when MK-801 is applied for a long time in the presence of NMDA. MK-801 is also effective at blocking NMDA-activated single-channel activity in outside-out patches. [3] MK-801 (< 500 μM) prevents LPS-induced activation of microglia in a concentration-dependent manner with increased Cox-2 protein expression in BV-2 cells. MK-801 (< 500 μM) reduces microglial TNF-α output with EC50 of 400 μM in BV-2 cells. [4] |
體內活性 | Treatment of mice with MK-801 (1 mg/kg) before each METH injection reduced the extent of DA depletion by 55% in striatal of mice. MK-801 (1 mg/kg) attenuates the effects of METH on microglial activation in striatal of mice. [4] MK-801 (0.05 mg/kg or 0.2 mg/kg, i.p.) in rats just prior to reactivation of the cocaine-associated memory in the CPP context attenuates subsequent cocaine-primed reinstatement, while no disruption occurres in rats that do not receive reactivation in the CPP context. MK-801 (0.2 mg/kg, i.p.) prior to two reactivation sessions in the home cage does not suppress subsequent cocaine-primed reinstatement. [5] |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 60 mg/mL (177.84 mM), Sonication is recommended. |
關鍵字 | MK 801 Maleate | inhibit | MK801 Maleate | anticonvulsant | neurotransmitter | noncompetitive | ambulation | MK801 | Dizocilpine Maleate | voltage | MK-801 | hyperlocomotion | MK-801 Maleate | Ionotropic glutamate receptors | Dizocilpine hydrogen Maleate | Inhibitor | iGluR | Mk-801 Hydrogen Maleate | Dizocilpine |
相關產品 | glycine | L-Glutamic acid | Linalool | L-Glutamic acid monosodium salt | Procaine hydrochloride | Riluzole | O-Phospho-L-serine | Halothane | Mephenesin |
相關庫 | 神經(jīng)保護化合物庫 | 抑制劑庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | 神經(jīng)遞質受體化合物庫 | 臨床前化合物庫 | 離子通道庫 | 神經(jīng)退行性疾病化合物庫 | 膜蛋白靶向化合物庫 | 疼痛相關化合物庫 |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 566.265100萬人民幣 |
員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 天然產物,生化試劑,分子生物學,分子砌塊,生物技術服務 | 經(jīng)營模式 | 貿易,工廠,試劑,定制,服務 |
產品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
¥3160.00 |
VIP9年
|
北京索萊寶科技有限公司
|
2024-11-07 | |
¥1744.90 |
VIP1年
|
上海阿拉丁生化科技股份有限公司
|
2024-08-16 | |
詢價 |
山西淵兮生物科技有限公司
|
2022-12-15 |